Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 17;24(6):997–1006. doi: 10.1038/cdd.2017.31

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Expression of profibrogenic markers TIMP1, MMP2 and collagen I in HSC supernatants. (a and b) HSCs were treated as described in Figure 4a. Top panel: the level of profibrogenic markers TIMP1, MMP2 and collagen I in HSC supernatants was assessed by western blot analyses. Bottom panel: HSC lysates were assessed for STAT1, p-STAT1 and β-tubulin expression. (c and d) Quantification of western blot results shown in (a or b). Values represent means±S.D. of 12 independent experiments (*P<0.05; **P<0.01). (e) Detection of profibrogenic markers TIMP1, MMP2 and collagen I in HSC supernatants after rIFN-γ treatment for 24 h. (f) Quantification of western blot results shown in (e) (*P<0.05; **P<0.01)